Prosecution Insights
Last updated: April 19, 2026
Application No. 18/522,058

INTRAOCULAR IMPLANTS AND METHODS AND KITS THEREFOR

Non-Final OA §102§103
Filed
Nov 28, 2023
Examiner
DEAK, LESLIE R
Art Unit
3799
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Sight Sciences Inc.
OA Round
1 (Non-Final)
75%
Grant Probability
Favorable
1-2
OA Rounds
3y 4m
To Grant
93%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allow Rate
693 granted / 924 resolved
+5.0% vs TC avg
Strong +18% interview lift
Without
With
+18.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
43 currently pending
Career history
967
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
47.9%
+7.9% vs TC avg
§102
25.1%
-14.9% vs TC avg
§112
11.4%
-28.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 924 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of pre-AIA 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent. Claims 13, 14, 19, 20, 27-31, and 33 are rejected under pre-AIA 35 U.S.C. 102(a) as being anticipated by US 2004/0193262 to Shadduck. In the specification and figures, Shadduck discloses the method as claimed by Applicant. With regard to claims 13, 14, 19, 20, 28-31 and 33, Shadduck discloses a method for reducing intraocular pressure in a glaucoma patient using a porous shape memory support 140 and an introducer 175 comprising positioning a distal end of the introducer near Schlemm’s canal, wherein the support comprises a compressed arcuate member located in a lumen of the cannula, and pushing the support into the core of Schlemm’s canal, such that the support, when expanded is fully contained within a portion of Schlemm’s canal, propping the canal open and allowing transmural flow (see FIGS 8, 12, 16, ¶0007-0008, 0042, 0044, 0057). With regard to claim 27, Shadduck discloses that in an embodiment, the support may extend entirely around the circumference of the anterior chamber, indicating that the support extends all the way around Schlemm’s canal (see ¶0068). With regard to claim 31, Shadduck discloses that the support may comprise a non-tubular shape (see FIGS 5B, 9B). Claim Rejections - 35 USC § 103 The following is a quotation of pre-AIA 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action: (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 21-26 and 32 are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over US 2004/0193262 to Shadduck. In the specification and figures, Shadduck discloses the method substantially as claimed by Applicant (see rejections above). With regard to claims 21, 22, 25, 26, Shadduck does not disclose the fluid flow rate claimed by Applicant nor the partial percentage of Schlemm’s canal that is occupied by the support. However, Shadduck discloses that a plurality of stents of various dimensions may be deployed in order to achieve tissue expansion in Schlemm’s canal (see ¶0045). Shadduck further discloses that tissue retraction affects outflow pathways and routes, teaching that stent properties may be used to influence flow rate (see ¶0003). It is within the skill of a worker in the art to select a porosity, dimension, and density of an apparatus disclosed in the prior art to generate a desired tissue expansion, thereby affecting the flow rate through Schlemm’s canal to the collector channels. With regard to claims 23 and 24, Shadduck does not disclose the claimed radii of curvature. However, it has been held that where the only difference between the prior art and the claims was a recitation of relative dimensions of the claimed device and a device having the claimed relative dimensions would not perform differently than the prior art device, the claimed device was not patentably distinct from the prior art device. See MPEP 2144.04(IV)(B). In the instant case, there is no showing that the radii of curvature claimed by Applicant is critical to the claimed method. With regard to claim 32, Shadduck discloses an embodiment wherein the implant is made of a shape memory alloy (see ¶0063). It would have been obvious to one having ordinary skill in the art at the time the invention was made to use a shape memory alloy as disclosed by Shadduck in the other embodiments disclosed by Shadduck, since it has been held to be within the general skill of a worker in the art to select a known material on the basis of its suitability for the intended use as a matter of obvious design choice. See MPEP § 2144.07. Claims 15 and 16 are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over US 2004/0193262 to Shadduck in view of US 2004/0127843 to Tu et al. In the specification and figures, Shadduck discloses the method substantially as claimed by Applicant (see rejections above). Shadduck does not disclose the use of a guidewire. However, Tu discloses a method of placing an ocular implant comprising a cannula 246, support 229E, and a guidewire 245 disposed within a central bore of support 229E to guide the support into the desired position (see FIGS 52A-D and accompanying text). Where a claimed improvement on a device or apparatus is no more than "the simple substitution of one known element for another or the mere application of a known technique to a piece of prior art ready for improvement," the claim is unpatentable under 35 U.S.C. 103(a). Ex Parte Smith, 83 USPQ.2d 1509, 1518-19 (BPAI, 2007) (citing KSR v. Teleflex, 127 S.Ct. 1727, 1740, 82 USPQ2d 1385, 1396 (2007)). Applicant claims a combination that only unites old elements with no change in the respective functions of those old elements, and the combination of those elements yields predictable results; absent evidence that the modifications necessary to effect the combination of elements is uniquely challenging or difficult for one of ordinary skill in the art, the claim is unpatentable as obvious under 35 U.S.C. 103(a). Ex Parte Smith, 83 USPQ.2d at 1518-19 (BPAI, 2007) (citing KSR, 127 S.Ct. at 1740, 82 USPQ2d at1396. Accordingly, since the applicant[s] have submitted no persuasive evidence that the combination of the above elements is uniquely challenging or difficult for one of ordinary skill in the art, the claim is unpatentable as obvious under 35 U.S.C. 103(a) because it is no more than the predictable use of prior art elements according to their established functions resulting in the simple substitution of one known element for another or the mere application of a known technique to a piece of prior art ready for improvement. In the instant case, it would have been obvious to a person having ordinary skill in the art at the time of invention to use a guidewire as disclosed by Tu as part of the support implantation process disclosed by Shadduck, since both methods were known at the time of invention. Claims 17 and 18 are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over US 2004/0193262 to Shadduck in view of US 6,375,642 to Grieshaber. In the specification and figures, Shadduck discloses the method substantially as claimed by Applicant (see rejections above). Shadduck does not disclose dilating Schlemm’s canal prior to support insertion. With regard to claims 17 and 18, Grieshaber discloses a method of dilating Schlemm’s canal by delivering high viscosity sodium hyaluronate solution to a patient comprising the steps of inserting a tubular cannula 29 at least partially within Schlemm's canal and using a probe/rod 24 to deliver the solution to Schlemm's canal, thereby expanding the lumen of the canal (see FIG 5, column 5, lines 1-34). Grieshaber further discloses that after the fluid injection, supports 30 may be placed within the lumen of the canal 19 (see column 6, lines 1-40). The support is flexible enough to conform to the curvature of the canal, yet firm enough to resist kinking (see column 6, lines 40-50). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to LESLIE R DEAK whose telephone number is (571)272-4943. The examiner can normally be reached Monday-Friday, 9am to 5:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sarah Al-Hashimi can be reached at 571-272-7159. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LESLIE R DEAK/Primary Examiner, Art Unit 3799 28 January 2026
Read full office action

Prosecution Timeline

Nov 28, 2023
Application Filed
Jan 28, 2026
Non-Final Rejection — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599497
IMPLANTS WITH CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING SAME
2y 5m to grant Granted Apr 14, 2026
Patent 12594186
AQUEOUS HUMOR DRAINAGE DEVICE WITH ADJUSTABLE TUBE DIAMETER
2y 5m to grant Granted Apr 07, 2026
Patent 12575972
GLAUCOMA STENT AND METHODS THEREOF FOR GLAUCOMA TREATMENT
2y 5m to grant Granted Mar 17, 2026
Patent 12569604
METHOD AND DEVICES FOR DETERMINING A TIME POINT FOR MEASURING PRESSURE MEASUREMENTS
2y 5m to grant Granted Mar 10, 2026
Patent 12569654
SYSTEMS AND METHODS FOR TREATMENT OF FLUID OVERLOAD
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
75%
Grant Probability
93%
With Interview (+18.0%)
3y 4m
Median Time to Grant
Low
PTA Risk
Based on 924 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month